For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 121,199 | |||
| General and administrative | 24,620 | |||
| Total operating expenses | 145,819 | |||
| Loss from operations | -145,819 | |||
| Interest income | 11,343 | |||
| Income from transition services agreements | 1,192 | |||
| Change in fair value of participation right liability | 725 | |||
| Other income (expense) | -35 | |||
| Total other income (expense), net | 11,775 | |||
| Net loss | -134,044 | |||
| Basic EPS | -4.3 | |||
| Diluted EPS | -4.3 | |||
| Basic Average Shares | 31,144,775 | |||
| Diluted Average Shares | 31,144,775 | |||
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)